DEFA14A: Masimo Defends Board Nominees Against Politan Capital's Challenge Ahead of 2024 Annual Meeting

Masimo urges stockholders to vote for its nominees, Joe Kiani and Christopher Chavez, highlighting Chavez's independence and medtech experience while criticizing Politan's nominees as potentially compromising the company's value.

Summary

• Masimo has issued a letter to stockholders defending its director nominees, Joe Kiani and Christopher Chavez, for the 2024 Annual Meeting.
• The letter contrasts Chavez's independence and medtech experience with Politan Capital's nominees, arguing that electing Politan's choices would jeopardize the value of stockholders' investments.
• Masimo's board emphasizes the need for robust discussion and objective counsel in the boardroom, asserting that Chavez is better qualified than Politan's nominees.
• The company criticizes Politan's claim that Masimo lacks independent oversight, calling it a false narrative.
• Masimo highlights Chavez's extensive experience in the medtech industry, including his past roles as a public company CEO and independent director.
• The letter questions the independence of Politan's nominees, suggesting they may be unduly influenced by the activist investor.
• Masimo's board expresses concern that Politan is seeking control of the company without a concrete transition and leadership plan.
• Masimo expects continued investments in R&D to support patient-focused, innovation-based revenue growth will allow Masimo to achieve $8 non-GAAP EPS in 5 years.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the document defends the company's position and highlights future EPS growth, it also acknowledges the challenges posed by the proxy fight with Politan Capital.

Positives

• Masimo is actively defending its board nominees against a challenge from Politan Capital.
• The company emphasizes the qualifications and independence of its nominee, Christopher Chavez.
• Masimo projects $8 non-GAAP EPS in 5 years, indicating confidence in its future performance.

Negatives

• Politan Capital is seeking to gain control of Masimo's board, creating uncertainty about the company's future direction.
• Masimo's board believes that Politan's nominees are inferior and could jeopardize the value of stockholders' investments.
• The company criticizes Politan for allegedly repeating a false narrative about independent oversight.

Risks

• Uncertainties regarding future actions that may be taken by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting.
• The potential cost and management distraction attendant to Politans nomination of director nominees at the 2024 Annual Meeting.

Future Outlook

Masimo expects continued investments in R&D to support patient-focused, innovation-based revenue growth will allow Masimo to achieve $8 non-GAAP EPS in 5 years.

Management Comments

• Masimo believes that ceding control of Masimo to Politan by electing its nominees would jeopardize the value of your investment in Masimo.
• The Board encourages stockholders to vote FOR Masimos highly qualified director nominees, Joe Kiani and Christopher Chavez.
• It is simply not the case that having met Joe Kiani in the past, whether at an industry event, on the opposite side of the negotiating table, or at a civic function, compromises the independence of our directors, creates an obligation to him or interferes with their duty to provide oversight.
• Politan is demanding control of Masimo without providing any concrete transition and leadership plan to shareholders.

Industry Context

The announcement reflects an ongoing proxy battle, a common occurrence in the corporate world where activist investors seek to influence company direction. This situation highlights the tension between management's vision and shareholder demands, particularly in the medtech industry where innovation and regulatory expertise are critical.

Comparison to Industry Standards

• The document mentions Anika Therapeutics, a company with a market cap well under $400 million, where one of Politan's nominees, William Jellison, serves as a board member as a nominee of activist investor Caligan Partners.
• Masimo highlights that Christopher Chavez has dealt with complex strategic, operational, regulatory and transactional matters unique to the medtech industry that neither Politan nominee and neither of the Politan directors has experienced.

Stakeholder Impact

• The outcome of the proxy vote could significantly impact the value of stockholders' investments.
• The company's future direction and innovation efforts could be affected by the composition of the board.
• The proxy fight could create uncertainty for employees and other stakeholders.

Next Steps

• Stockholders are encouraged to vote on the director nominees at the 2024 Annual Meeting.
• Masimo will continue to engage with stockholders to communicate its views on the nominees and the company's strategy.

Key Dates

Keywords

Masimo, Politan Capital, proxy fight, annual meeting, director nominees, Christopher Chavez, Joe Kiani, board of directors, medtech, stockholders